France: AI & The Quest for Life Sciences 4.0
With Minister of the Economy and Finance, Bruno Le Maire, emphasizing the importance of “winning the battle on data” and eccentric mathematician Cédric Villani, well in the process of drawing…
The Swiss company SIGVARIS, 100% family-owned since it was founded, is the global market leader in the manufacture of medical compression garments and celebrated its 150th anniversary in 2014. The company was established in 1864 in Winterthur. For about 100 years, SIGVARIS produced “rubber-elastic textiles”, which it sold both in Switzerland and abroad.
From 1958 to 1960, the company collaborated with Dr. Karl Sigg and developed a medical compression stocking to improve venous function and relieve venous-related conditions. The product portfolio was expanded in 2009 when the WELL BEING and SPORTS lines were added to the main MEDICAL line. WELL BEING stockings have a preventive function and relieve the early symptoms of leg conditions. SPORTS products improve athlete performance and recovery time.
The company can look back at a successful track record as it moves continuously towards the future, in keeping with its motto “Every day a step further”. Customers around the world include pharmacies, chemists, orthopaedic and medical specialist stores as well as doctors and hospitals. The Group produced about 8 million pairs of stockings in 2014 and generated revenue of around CHF 250 million.
SIGVARIS Group
The Swiss Group SIGVARIS has its headquarters in Switzerland and is the global market leader in the manufacture of medical compression garments. It employs about 1,400 people and has its own production plants in Switzerland, France, the US and Brazil. SIGVARIS is close to its customers, having subsidiaries in Germany, Austria, England, Italy, Canada, China, Australia and the United Arab Emirates as well as distributors in more than 70 countries on all continents. The Group pursues an international growth strategy on the solid foundation of 150 years of success.
Contact
Rue Barthélémy Thimonnier, 42170 Saint-Just-Saint-Rambert, France
+33 4 77 36 08 90
With Minister of the Economy and Finance, Bruno Le Maire, emphasizing the importance of “winning the battle on data” and eccentric mathematician Cédric Villani, well in the process of drawing…
France – one of the most influential countries in the development of gene therapy– still stands as a global powerhouse in the field, with top-class institutions, a dense network of…
With a feel-good factor sweeping French innovative pharma, the country’s iconic mid-cap biopharma standard-bearers are once more on the rise. These medium-sized national champions form part of G5 Santé, a…
Francois Cornu, president of Eurofins Biomnis, and Gautier Decock, managing director of Eurofins BioPharma Product Testing in France and Belgium, come together to shed light on the company’s unique decentralized…
Nathalie Giraud, director of integrated monitoring investigator services & head of France at PPD, breaks down the strengths and weaknesses of the French clinical trials environment and stresses the importance…
The latest issue of Healthcare & Life Sciences Review France follows on from our March 2019 report and takes a closer look at the wider French life sciences value chain…
Not long ago, Laboratories Servier was considered a somewhat mysterious and opaque actor on the world pharmaceuticals stage. Privately owned, smaller and sleeker than many of its direct competitors, but…
Iconic French skincare specialist, Pierre Fabre has been enjoying a hot streak of late, with its dermo-cosmetics business registering hefty sales growth of more than EUR 350 (USD 392) million…
Christopher Cuniasse, managing director of Fagron France, sheds light on the specialty area of pharmaceutical compounding and its link with personalized medicine, noting the benefits it can deliver to health…
Éric Ducournau, global CEO of Pierre Fabre Group, the second largest dermo-cosmetic company worldwide and the third-largest French pharmaceutical laboratory, provides insights into the group’s on-going internationalization and its emerging…
Inventiva is a French clinical-stage biotech company focused on developing oral small molecule epigenetic modulators in therapeutic areas with high unmet medical needs such as fibrosis, lysosomal storage disorders and…
Inotrem is a French biotech company developing a novel approach to target inflammatory diseases based on the TREM-1 pathway. Its CEO, Dr Jean-Jacques Garaud explains why he decided to leave…
See our Cookie Privacy Policy Here
